Gamma interferon-dependent clearance of cytomegalovirus infection in salivary glands by Lucin, Pero et al.
JOURNAL OF VIROLOGY, Apr. 1992, p. 1977-1984
0022-538X/92/041977-08$02.00/0
Copyright © 1992, American Society for Microbiology
Gamma Interferon-Dependent Clearance of Cytomegalovirus
Infection in Salivary Glands
PERO LUCIN,l IVICA PAVIC,1 BOJAN POLIC,l STIPAN JONJIC,' AND ULRICH H. KOSZINOWSKI2*
Department of Physiology and Immunology, Faculty of Medicine, University of Rijeka, 51000 Rijeka, Croatia,'
and Department of Virology, Institute for Microbiology, University of Ulm, D-7900 Ulm, Germany2
Received 4 October 1991/Accepted 16 December 1991
Cytomegalovirus (CMV), similar to other members of the Herpesviridae family, can establish both persistent
and latent infections. Each of the CMVs that are found in many animal species replicates in the salivary gland,
and oral secretion represents a source of horizontal transmission. Locally restricted replication characterizes
the immunocompetent individual, whereas in the immunocompromised host, protean disease manifestations
occur due to virus dissemination. The virus is cleared by immune surveillance, and CD8+ T lymphocytes play
a major role. Remarkably, certain cell types of salivary gland tissues are exempt from CD8+ T-lymphocyte
control of murine CMV infection and require the activity of CD4+ T Iymphocytes. The results presented here
suggest that this activity is a function of Thl cells. Neutralization of endogenous gamma interferon abrogated
the antiviral activity of Thl cells but not that of CD8+ T lymphocytes in other tissues. Neutralization of
endogenous gamma interferon did not interfere with the induction of the cellular and humoral immune
response but acted during the effector phase. Recombinant gamma interferon could not replace the function of
Thl cells in vivo and had limited direct antiviral activity in vitro. The results therefore suggest that gamma
interferon represents one, but not the only, essential factor involved in salivary gland clearance, establishment
of CMV latency, and, eventually, the control of horizontal transmission.
Cytomegalovirus (CMV), a member of the herpesvirus
family, establishes acute and chronic infections. After pri-
mary infection, CMV remains in the host in a latent state
from which reactivation can occur. Infection of immuno-
competent hosts is usually asymptomatic, whereas infection
or virus reactivation in the immunocompromised host can
cause severe and fatal disease. CMV is a serious problem for
patients with organ transplants and represents the most
frequent viral cause of death in patients with AIDS (6, 18).
Studies on infection of mice with murine CMV (MCMV),
a model for CMV disease, have shown that although natural
killer (NK) cell functions are associated with resistance to
infection with high doses of virus, survival requires the
presence of T lymphocytes (33). In our own studies con-
cerned with the adoptive immunotherapy of the imimuno-
compromised infected host, we were able to identify CD8+ T
lymphocytes as a major protective principle (reviewed in
reference 16). With the mouse model, the definition of major
antigens (24), the identification of antigenic peptides pre-
sented by major histocompatibility complex (MHC) class I
molecules (26), the principles of variable antigen presenta-
tion during viral replication (3), and the construction of
experimental recombinant vaccines (4, 5, 10, 32) have been
carried out.
Still, analysis of the protective immune mechanisms oper-
ative during acute infection failed to explain a long-estab-
lished notion, namely, the production of CMV in salivary
gland tissues and virus excretion even by immunocompetent
hosts. Ultrastructural examinations have located the acinar
glandular epithelial cells as the site of chronic infection (9).
Recently, we reported that, unlike in all other tissues tested,
CD8+ T lymphocytes alone cannot clear (11) and CD4+ T
lymphocytes are essential for the clearance of salivary gland
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tissues, a function that does not even require the contribu-
tion of CD8+ T lymphocytes (12).
In this study, we have characterized the CD4 T-lympho-
cyte subset involved. We identified the protective CD4
subset as Thl cells by the correlation between function and
endogenous gamma interferon (IFN-y) activity. We report
that neutralization of IFN-y abolishes the antiviral activity of
CD4+ but not of CD8+ T lymphocytes. Because recombi-
nant IFN-y (rIFN-y) cannot replace Thl cells and has limited
direct antiviral activity, this cytokine probably represents
only one of the essential factors required for the establish-
ment of viral latency in the infected host.
MATERIALS AND METHODS
Mice. Female BALB/c (H-2d) and CBA/J (H-2k) mice, 7 to
9 weeks old, were obtained from our own breeding colony.
Thymectomized mice were prepared by the standard proce-
dure for adult thymectomy (12).
Virus, virus titrations, and infection conditions. Sucrose
gradient-purified mouse embryo fibroblast culture-propa-
gated MCMV (Smith strain; code VR-194; American Type
Culture Collection, Rockville, Md.) was used. MCMV in
tissues was quantified by a plaque assay (27). The detection
limit was 100 PFU of MCMV per organ homogenate. Virus
titers (X versus were regarded as significantly different for
P (X versus Y) a = 0.05 (one-sided), where P is the observed
probability value and a is a selected significance level
(Wilcoxon-Mann-Whitney exact rank sum test).
A plaque reduction assay was used to test the in vitro
antiviral activity of rIFN-y. Second-passage mouse embryo
fibroblasts, grown in Dulbeco's modified Eagle's medium
supplemented with 3% fetal calf serum (GIBCO), were
seeded in 24-well tissue culture plates (105 cells per well),
and various concentrations of rIFN-y were added. After 24
h, the monolayers were infected with MCMV (200 PFU/
well). After adsorption for 30 min at 37°C, the plates were
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FIG. 1. Effect of CD4 subset depletion on the course of MCMV infection in the salivary gland of resistant and susceptible mouse strains.
The effect of long-term CD4 subset depletion was studied in CBA and BALB/c mice. Individually scored titers are shown by solid circles (S),
and median values are marked by horizontal bars (-). The dashed line indicates the detection limit (DL). Virus titers in groups of
CD4-depleted mice differed significantly (P = 0.005) from virus titers in immunocompetent mice of either strain.
centrifuged at 800 x g for 30 min. The cultures were then
overlaid with medium containing methyl cellulose and incu-
bated for a further 96 h in the presence of rIFN--y. For
intraplantar infection, a dose of 2 x 105 PFU was used
throughout.
Reagents and antibodies. Recombinant murine IFN-y was
generously provided by G. R. Adolf, Bender Vienna, Vi-
enna, Austria. The specific activity of rIFN--y (lot no.
M3-RD48) was 107 U/mg, as determined by the L cell-
encephalomyocarditis virus bioassay. Diluent vehicle for in
vivo and in vitro studies was sterile Dulbeco's Ca2'- and
Mg2+-free phosphate-buffered saline (PBS; GIBCO Labora-
tories). Monoclonal antibodies (MAbs) included 191.1 (rat
immunoglobulin G2b [IgG2b]) (2), which recognizes the
murine CD4 antigen; 169.4 (rat IgG2b) (2) and 19.178 (mouse
IgG2a) (8), both specific for the murine CD8 antigen; and
R4.6A2 (rat IgGl), which neutralizes murine IFN-y (30).
Antibodies were partially purified from ascitic fluid or tissue
culture supernatant by 50% ammonium sulfate precipitation,
followed by dialysis in PBS (pH 7.6), and stored at -30°C
until use. The concentration of rat IgG in the MAb stocks
used in vivo was determined by a radial immunodiffusion
assay with rat and mouse IgG standards (Serotec, Oxford,
England). The IFN-y-neutralizing capacity of MAb R4.6A2
stocks was determined in a cell protection assay on an L929
monolayer grown in 96-well flat-bottomed plates after infec-
tion with vesicular stomatitis virus, using a standard tech-
nique described elsewhere (18). The neutralizing capacity of
the anti-IFN--y MAb stock was ca. 5 X 104 U/mg.
In vivo treatment of mice. In vivo depletion of CD4+ and
CD8+ T-lymphocyte subsets was carried out as described
previously (11, 12). In thymectomized mice, long-term de-
pletion of the CD4 and CD8 subsets was accomplished by
intravenous treatment with anti-CD4 or anti-CD8 MAb,
respectively, at a dose of ca. 1 mg for 3 successive days. A
single antibody injection was repeated after 7 days. For
short-term depletion of T-cell subsets, immunocompetent
mice as well as adoptive lymphocyte transfer recipients were
injected intraperitoneally with 1 mg of anti-CD4 or anti-CD8
MAb every fourth day, starting 1 h after infection and cell
transfer. For in vivo neutralization of IFN--y, mice were
injected with 1 mg of R4.6A2 MAb in 0.5 ml of PBS for 2
successive days starting from the day of infection. Every
third day, another single injection of 1 mg of anti-IFN--y
antibody was carried out. Experiments were terminated
after 2 weeks.
The in vivo activity of rIFN--y was tested by injecting mice
with a single dose of 2 x 104 U of rIFN-y intraperitoneally
every other day for the test period of 2 weeks. Control mice
received PBS.
The prophylactic adoptive cell transfer was performed as
described previously (27). In brief, recipient mice were
immunodepleted by total-body gamma irradiation, with 6 Gy
delivered as a single dose. Spleen lymphocytes from donor
mice were infused into the tail vein 2 h after irradiation and
infection. Virus titers in tissues of recipients were deter-
mined 2 weeks later.
Cytofluorometric analysis. For cytofluorometric analysis
(FACScan; Becton Dickinson & Co., Mountain View, Calif.)
of the distribution of the CD4 and CD8 subsets, lymphocytes
were stained simultaneously by phycoerythrin-conjugated
anti-L3T4 MAb and fluorescein isothiocyanate-conjugated
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FIG. 2. Effect of IFN--y neutralization on the course of MCMV
infection in salivary glands. CBA and BALB/c mice were compared
with respect to virus production in the salivary glands 2 weeks
postinfection. Groups of mice were treated with antibodies to
IFN-,y, CD4, or CD8. Control groups of mice received rat IgG (0).
Titers in individual mice (@) and median values (-) are shown. DL,
detection limit. There is a significant difference in virus titers
between mice treated with anti-IFN-y and control serum for CBA
mice (P = 0.005) and BALB/c mice (P < 0.01).
anti-Lyt-2 MAb (Becton Dickinson). The expression of
MHC class I antigens on thymocytes was analyzed by
indirect immunofluorescence. The cells were incubated with
hybridoma supernatant (28-14-8, anti-Ld) (21) as a first
reagent, and after washing, the binding of the first antibody
was visualized by the fluoresceinated secondary antibody
(fluorescein isothiocyanate-conjugated goat anti-mouse im-
munoglobulin [Becton Dickinson]). The fluorescence signal
was triggered on particles larger than platelets, and propid-
ium iodide (1 ,ugIml)-stained dead cells were excluded by
electronic gating. Relative fluorescence intensities were ex-
pressed in a log scale, with 104 cells analyzed.
Detection of specific antibodies. The enzyme-linked im-
munosorbent assay (ELISA) for quantitating MCMV-spe-
cific antibodies and the plaque reduction assay for determi-
nation of titers of virus-neutralizing antibodies have been
described previously (10). The antibody response of mice to
rat IgG, after treatment with rat MAb in vivo, was monitored
by ELISA with purified rat IgG as the antigen.
RESULTS
CD4 subset required for virus clearance from salivary gland
tissues. The importance of the CD4 T-lymphocyte subset in
clearance of CMV infection and establishment of latency
was shown previously for the BALB/c (H-2d) strain of mice
(11). This mouse strain is highly susceptible to MCMV
disease, whereas other strains, such as CBA (H-2k), are
significantly more resistant (23). We therefore asked whether
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FIG. 3. Generation of antiviral effector cells in anti-IFN-y-
treated mice. Two weeks after infection, spleen cells (106) from
donor mice were transferred into immunodepleted recipient mice to
determine their antiviral activity. Depicted are titers in lungs for
individual recipients, determined 2 weeks after cell transfer and
infection (0), as well as median values (-). A, nonprimed donors;
B, MCMV-primed donors treated with control rat IgG; C, MCMV-
primed donors treated with anti-IFN-y MAb. DL, detection limit.
the requirement for CD4 lymphocytes for virus clearance
characterizes only the susceptible BALB/c strain or repre-
sents a general mechanism. Immunocompetent and CD4
subset-depleted mice of both strains were infected with 2 x
105 PFU ofMCMV, and the kinetics of virus clearance in the
salivary gland, the organ which is cleared last during CMV
infection, was studied. As shown in Fig. 1, the more resis-
tant CBA mice had lower virus titers and cleared virus faster
from the salivary glands than did BALB/c mice. Three to 4
weeks after infection, most of the CBA mice had already
terminated the productive virus infection. CD4 subset deple-
tion, however, led to augmented virus replication restricted
to the salivary gland tissues, resulting in persistent MCMV
infection comparable to the situation seen in CD4 subset-
depleted BALB/c mice. In accordance with previously pub-
lished data for the BALB/c strain (12), CD8 depletion did not
prevent virus clearance in CBA mice (data not shown).
Thus, the requirement for CD4' T lymphocytes apparently
represents a general mechanism.
In vivo neutralization of endogenous IFN-y prevents virus
clearance. It was of interest to understand by what mecha-
nism CD4+ T lymphocytes contribute to virus clearance. By
the type of cytokines they secrete, murine CD4+ T-helper
lymphocytes can be divided at the clonal level into at least
two subsets (19), T-helper 1 cells (Thl) and T-helper 2 cells
(Th2) (19). Thl cells are characterized by the production of
interleukin-2 (IL-2), IFN-y, and lymphotoxin (20). We had
observed that the protective effect of CD4+ T lymphocytes
requires the cooperation of the CD4 subset with other cells,
which to us appeared indicative of cytokine involvement
(12). To test the contribution of endogenously produced
IFN--y, mice were treated with anti-IFN-y antibody R4.6A2
to neutralize the endogenous activity of IFN--y. The effect of
anti-IFN--y treatment was compared with the known effect of
anti-CD4 and anti-CD8 antibody treatment (Fig. 2). Neutral-
ization of IFN-y abolished virus clearance from the salivary
gland to a degree similar to that resulting from CD4 subset
depletion, whereas elimination of the CD8 subset had no
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TABLE 1. In vivo neutralization of IFN--y does not alter the
virus-specific antibody response
No. of Antibody titer
Group Treatment in No.potGvivo pice ELISA' Virusmice ELISA' neutralization"
Noninfected 0/5 <8 <8
Infected Rat IgG 5/5 512 32
Anti-CD4 0/5 <8 <8
Anti-IFN--y 5/5 256-512 64
a Serum was taken 3 weeks after MCMV infection, and virus-specific
antibodies were determined by an ELISA. Data represent the reciprocals of
serum dilutions (pooled from five mice) that gave a positive reaction (3
standard deviations above the control).
b The in vitro neutralizing activity of individual sera was determined as
described in Materials and Methods. Data represent the reciprocals of the
serum dilutions that gave 50% neutralization.
effect. These results suggest that Thl cells releasing IFN-y
have a central role in T-lymphocyte-mediated MCMV clear-
ance from salivary gland tissues.
IFN--y neutralization does not prevent induction of the
antiviral immune response. Cytokines have complex effects,
and neutralization of IFN--y could either block the generation
of the specific immune response to MCMV or inhibit the
effector phase. We first studied the effect of IFN--y neutral-
ization on generation of the protective T-lymphocyte re-
sponse. Spleen cells from MCMV-infected and anti-IFN--y-
treated BALB/c mice and spleen cells from control mice
receiving isotype-matched irrelevant antibody were tested
for their capacity to limit virus spread after adoptive transfer
into MCMV-infected and gamma-irradiated syngeneic recip-
ients. The irradiation protocol of 6 Gy is equivalent to the
lethal dose of 50% of the mice within 30 days and abolishes
the capacity of recipient mice to mount a specific immune
response during the test period (15, 27). Two weeks later,
recipients were killed, and virus titers in their organs were
determined (Fig. 3). Unlike cells from nonprimed cell donors
(Fig. 3A), the same number of cells (106) from MCMV-
primed mice showed a strong antiviral effect (Fig. 3B and C),
which is the function of CD8+ T lymphocytes. The degree of
virus titer reduction was comparable between recipients of
cells from MCMV-primed donors treated with anti-IFN--y
and recipients of cells from donors receiving only control
antibody. Therefore, neutralization of IFN--y did not appar-
ently interfere with the maturation of antiviral effector cells.
To study the potential effect of IFN--y on the production of
antiviral antibodies, sera derived from anti-IFN-y-treated
mice and from control animals were analyzed for virus-
specific antibodies. Titers were determined by an ELISA
and by virus neutralization. No significant difference be-
tween these two groups of mice was seen, which indicated
that IFN--y neutralization is without effect on the magnitude
and biological activity of the MCMV-specific antibody re-
sponse (Table 1).
IFN--y required for CD4+ but not for CD8+ T-lymphocyte
effector functions. In the absence of a major effect of IFN--y
neutralization during the induction phase of the specific
immune response, we studied whether IFN--y neutralization
did interfere with antiviral T-lymphocyte effector functions
in vivo. This function of T lymphocytes was again tested in
an adoptive cell transfer system. Unlike in the experiment
described above, not only donors but also cell recipients
were treated. MCMV-primed cell donors were either fully
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FIG. 4. Neutralization of endogenous IFN--y prevents the antivi-
ral activity of MCMV-primed CD4+ lymphocytes in salivary gland
tissues. Spleen cells (106) from immunocompetent or CD8 subset-
depleted MCMV-primed donors were transferred into irradiated and
MCMV-infected syngeneic recipient mice for in vivo assessment of
antiviral activity. Recipient mice were divided into three subgroups,
receiving either purified rat IgG (0), rat MAb to CD4, or rat MAb to
IFN-y. Virus titers in individual recipient organs, measured 2 weeks
after transfer and infection (0), and median values (-) are shown.
Control level (CL) represents the effect on cells from nonprimed
control donors.
immunocompetent or CD8 subset depleted. The irradiated
and MCMV-infected cell recipients received, on the day of
cell transfer (2 x 105 cells), either control immunoglobulins
or antibodies to CD4 or IFN-y. Comparable effects on virus
titers in salivary gland tissues were seen with donor cells
from immunocompetent and from CD8-depleted mice (Fig.
4), demonstrating again that it is mainly the CD4 T-lympho-
cyte subset which contributes to virus clearance in this
organ. In line with this fact was that treatment with anti-CD4
abolished the protective activity of both donor cell popula-
tions. Treatment of recipients with anti-IFN--y had an effect
comparable to that of anti-CD4 injection. Although not
significant in this experiment, nevertheless, it was an invari-
able observation in several similar experiments that, after
anti-CD4 treatment, the resulting virus titer was even higher
than after anti-IFN-y administration, indicating that anti-
IFN-y significantly but perhaps not completely eliminated
the antiviral activity of the CD4 subset. Together, these data
show that IFN-y is required mainly during the effector phase
and that it is crucial for the clearance ofMCMV infection by
the primed Thl subset of CD4+ T lymphocytes.
The situation was different when virus titers were studied
in those tissues in which mainly CD8+ T lymphocytes limit
MCMV replication (Fig. 5). In the lungs and the spleen,
elimination of the CD4 subset, as expected from the results
of previous studies (11, 12), did not abolish the control of
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FIG. 5. Effect of IFN-y neutralization on virus clearance from
lungs and spleen after transfer of MCMV-primed lymphocytes.
Spleen cells (2 x 105) derived from immunocompetent mice, either
MCMV primed or nonprimed, were transferred into MCMV-in-
fected recipient mice that were immunodepleted by sublethal gam-
ma-irradiation. Recipients of cells received either purified rat IgG
(0), rat anti-CD4, rat anti-CD8, or rat anti-IFN-y. Shown are titers
for individual recipients, determined 2 weeks after transfer. DL,
detection limit.
virus spread. Although there was some effect of CD4 deple-
tion on virus titers in the lungs, only elimination of the CD8
subset abolished the protective activity. Treatment of recip-
ients with antibodies to IFN--y had an effect similar to the
removal of the CD4 T-lymphocyte subset. Therefore, unlike
the effector function of the CD4 subset in the salivary gland,
the activity of the CD8 subset operative in other tissues is
not dependent upon endogenous IFN--y activity.
rIFN-y cannot replace the antiviral CD4 subset functions in
vivo. CD4 T-lymphocyte-depleted mice develop a chronic
productive infection of the salivary gland, whereas CD8
T-lymphocyte-depleted animals clear this tissue (12). Since
anti-IFN--y administration abolished the function of the CD4
subset in the salivary glands, we asked whether IFN--y is the
main effector molecule and whether it can replace the CD4
T-lymphocyte function in the salivary glands. Three exper-
imental protocols were carried out (Table 2). First, infection
and administration of rIFN--y were initiated simultaneously
in irradiated mice. Second, mice were depleted only for the
CD4 subset, infected, and injected with rIFN--y. Third, mice
were depleted for the CD4 subset and infected, but rIFN-y
injection was delayed until 2 weeks after the infection. In all
three groups, rIFN-,y treatment was continued for 2 weeks,
and the effect on virus titers in the salivary gland was tested.
In none of the experiments was a therapeutic effect of
rIFN--y administration detectable. This was concluded from
the observation that in irradiated mice, the virus titers of
saline- and rIFN--y-injected mice were comparable (group
A). rIFN--y could not diminish or prevent the effect of CD4
subset removal (groups B and C). rIFN--y injection, how-
ever, was not without any biological activity in vivo, since
the lymphocytes reconstituting the thymus after irradiation
that were obtained from mice treated according to the first
protocol showed enhanced MHC class I antigen expression
TABLE 2. Injection of rIFN--y does not affect MCMV replication
Range of
virus titers
Protocol" Treatment in salivary
glandsb
(loglo PFU)
A PBS 6.3-6.8
rIFN-y 6.1-6.3
B Rat IgG 3.8-4.1
Anti-CD4 5.1-5.7
Anti-CD4 + rIFN-y 4.9-5.6
C Rat IgG <2-3.8
Anti-CD4 5.5-6.0
Anti-CD4 + rIFN--y 5.3-6.3
" A, Irradiated (6 Gy) and MCMV-infected BALB/c mice were injected
with 2 x 104 U of rIFN-y every other day for 2 weeks; B, thymectomized and
MCMV-infected BALB/c mice were treated with anti-CD4 or control rat IgG
and MCMV infected. rIFN-y treatment (2 x 104 U) was initiated at the same
time and continued every other day for 2 weeks; C, thymectomized BALB/c
mice were depleted of CD4+ T lymphocytes and MCMV infected. rIFN-y (2
x 104 U) treatment was initiated after 2 weeks of infection and repeated every
other day for another 2 weeks.
Six mice were used per group. The data represent the range of titers found
in individual mice.
(Fig. 6). Considering that a similar dose of rIFN--y proved to
be efficacious during bacterial (14, 29), parasitic (28), and
viral (15) infection, we concluded that IFN-y alone cannot
substitute for the function of the CD4 subset.
Weak antiviral effect of rIFN-y in vitro. The results de-
scribed above predicted that rIFN--y should not have a
strong direct antiviral effect. This question was addressed by
a plaque reduction assay (Fig. 7). Permissive murine embryo
fibroblasts were incubated with different concentrations of
rIFN-y prior to infection with MCMV, and rIFN--y was also
maintained in the medium throughout the test period.
Plaques were counted 96 h following infection. There was
only a minimal effect of rIFN--y on plaque numbers at
physiological concentrations of the cytokine, indicating that
the capacity of IFN--y to induce an antiviral state in fibro-
blasts is low. Only at a concentration of 100 U of IFN--y and
higher was the number of MCMV plaques decreased signif-
icantly.
DISCUSSION
Limitation of acute infection and establishment of viral
latency are the hallmarks of an efficient host immune sur-
veillance during a herpesvirus infection. NK cells are active
during the first days of infection (33), and the control of acute
MCMV disease is an essential function of CD8+ T lympho-
cytes (27), whereas final clearance of productive infection
and establishment of latency in the salivary gland require
CD4+ T lymphocytes. In the absence of clearance, a per-
sistent state of viral infection is established (11). The spread
to other tissues is under control of the CD8 subset, and
antibodies probably also contribute. Thus, CD4+ T lympho-
cytes have a pivotal role in establishment ofMCMV latency
and the prevention of horizontal transmission. Conse-
quently, it is necessary to evaluate their physiological role in
vivo. Here we report three major findings. First, the antiviral
activity of the CD4+ T lymphocytes is a function of the Thl
subset; second, the protective effector function of CD4+ but
not of CD8+ T lymphocytes is associated with the release of
the cytokine IFN-y; and third, the role of IFN-y in the
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FIG. 6. Enhancement of MHC class I antigen expression after
treatment with rIFN--y in vivo. Cytofluorometric analysis of CD4+
and CD8+ cells and expression of MHC class I antigens (Ld) in
thymocytes derived from sublethally irradiated and MCMV-infected
mice 2 weeks after adoptive transfer of 105 nonprimed spleen cells.
(a and b) Fluorescence profiles of mice treated with PBS. (c and d)
Fluorescence profiles of mice injected with 2 x 104 U of rIFN--y
every other day for 2 weeks, starting on the day of infection. PE,
phycoerythrin; FITC, fluorescein isothiocyanate.
enhancement of host resistance to MCMV infection is prob-
ably not due to the direct antiviral activity of this cytokine.
Although intermediate patterns do exist, CD4+ murine
T-lymphocyte clones usually exhibit distinct patterns of
cytokine production (20). The observation that Thl cells
have a beneficial effect during the immune response to
parasite infections (22, 28) stimulated us to test Thl cell
function. Thl cells but not Th2 cells produce IL-2, IFN-y,
and lymphotoxin, whereas Th2 but not Thl cells release
IL-4, IL-5, IL-6, and IL-10 (20). The significance of IFN--y
for virus clearance is established for members of the arena-
virus (15, 17), the poxvirus (13), and the myxovirus (31)
families. We therefore reasoned that, to identify a beneficial
contribution of Thl cells to the control of MCMV infection,
neutralization of one of the essential cytokines of Thl cells,
IFN-y, should provide a clue. Given the dichotomy of helper
T cells, our observation that anti-IFN--y antibody largely
abolished CD4 T-lymphocyte-dependent virus clearance in
salivary gland tissues suggests that the protective function is
a property of the Thl subset. This is in agreement with our
observation that in vivo administration of anti-IL-4 antibody
had no measurable effect on MCMV virus titers (10a).
CD8+ T lymphocytes exhibit a cytokine secretion pattern
which is indistinguishable from that of Thl cells. Because
MCMV-specific CD8+ T lymphocytes have a powerful role
in MCMV clearance, it was essential to define their contri-
bution. The effect of CD8+ T lymphocytes was excluded by
the following results. First, virus clearance in the salivary
gland is a function associated with CD4 cells, and mice
lacking the CD4 subset do not clear this organ (11, 12).
Second, as shown here, despite the presence of both subsets
in the transferred effector cell population, the treatment of
immune-cell recipients with either anti-CD4 or anti-IFN-y
antibody resulted in the loss of protective function. Third,
the antiviral effect of CD8+ T lymphocytes was not abol-
ished by IFN--y neutralization. Therefore, the IFN--y re-
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FIG. 7. Effect of rIFN-y on MCMV replication in vitro. Murine
embryonic fibroblasts were incubated for 24 h with the indicated
concentrations of rIFN-y prior to infection with 200 PFU of MCMV.
rIFN-y was maintained throughout the incubation period of 4 days,
after which plaques were counted.
leased under these conditions probably originates from the
CD4 subset.
Neutralization of endogenous IFN--y indicated a physio-
logical role of this cytokine in the enhancement of host
resistance to a herpesvirus. Due to the pleiotropic effect of
IFN-y, it was necessary to identify at which step cytokine
neutralization interferes with the physiological immune re-
sponse. IFN-y could act during the induction phase, either
by modulating the activation of lymphocytes, macrophages,
or NK cells, by regulating MHC class I and class II expres-
sion, or by affecting the regulation of the isotype-specific
antibody response, or during the effector phase of the
immune response. This situation is apparently different for
the different viruses that have been tested. In a retrovirus
model, neutralization of endogenous IFN--y inhibited the
activation of specific cytotoxic T lymphocytes (7), whereas
picornavirus and rhabdovirus responses were not affected
(15). Our finding that the same conditions that prevented the
T-cell-mediated clearance of salivary gland tissue allowed
the generation of an effector cell response that was indistin-
guishable from that seen in the absence of IFN--y neutrali-
zation led us to conclude that the major effect of IFN--y
neutralization seen in this study does not affect the induction
of the cellular antiviral immune response.
IFN-y neutralization in vivo did not cause detectable
differences in the titer of neutralizing antibodies. There was,
however, a clear effect on the relative representation of the
different immunoglobulin isotypes (17a). The hypothesis that
different antibody isotypes to MCMV play a major role was
considered unlikely, since clearance of the salivary gland is
not correlated with antibody titers even in the fully immu-
nocompetent animal (25). Altogether, the experimental evi-
dence suggested that the neutralization of endogenous IFN--y
should mainly affect the effector phase. Proof included the
observation that the function of adoptively transferred CD4+
T lymphocytes, but not of CD8+ lymphocytes, was blocked
by anti-IFN--y antibody.
NK cells are also producers of IFN-y. In experiments to
show an antiviral function of enriched NK cells in the
adoptive cell transfer model, however, about 100-fold more
cells were required to see an effect on virus titers in the
spleen, the organ most susceptible to the influence of trans-
ferred cells (1). Therefore, we considered the essential
contribution of IFN--y by NK cells unlikely.
How to explain the function of IFN-y in the effector phase
of Thl cells? Our finding that IFN--y could not replace the
function of the CD4 subset in vivo and the limited activity of
IFN--y at physiological concentrations argue against a direct
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role of this cytokine. It should be recollected that the basis of
the persistent infection in salivary gland tissue is the immune
escape of one cell type, glandular epithelial cells, from CD8
subset control (11). This is the only cell type we have
identified so far that requires the function of the CD4 subset,
and, as shown here, the additional presence of IFN--y. Other
cells in the salivary gland are still subject to CD8 subset
control. Two mechanisms can be considered. The cytokine
could be required for MHC class II upregulation and the
subsequent recognition of MCMV peptides by CD4+ T
lymphocytes with cytolytic function. The other possibility,
which is favored by us, is that IFN--y must synergize with
other CD4 subset-derived cytokines, or cytokines induced
by IFN-y in other cells, to result in virus clearance of this
particular cell type.
In conclusion, our studies in a model system for CMV
disease have revealed that, in contrast to other tissues, the
acinar cells of the salivary gland are exempt from CD8
subset control. These cells represent a source of chronic
productive virus infection and thus a source of horizontal
CMV transmission. Infection of this cell type is under CD4
subset control, i.e., the control of Thl cells. Virus clearance
by Thl cells requires the function of IFN--y. Because rIFN-y
cannot replace Thl cells and has little direct antiviral activ-
ity, IFN-y probably acts in concert with other effector
mechanisms which are presently under study.
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